Showing 1070 – 1080 of 1158 results
-
Solid Biosciences Inc Initiation
William Blair initiated research coverage of Solid Biosciences Inc. (SLDB $13.57), a development-stage biopharmaceutical company focused on gene therapies for rare neuromuscular and cardiac diseases.
-
Vigil Neuroscience Inc Initiation
William Blair initiated research coverage of Vigil Neuroscience, Inc. (VIGL $2.47), a clinical-stage biopharma focused on developing microglial-targeting therapeutics by leveraging genetic insights into degenerative disorders of the central nervous system (CNS).
-
Gilat Satellite Networks Ltd Initiation
William Blair initiated research coverage of Gilat Satellite Networks Ltd. (GILT $4.96), an Israel-based provider of satellite communications infrastructure.
-
Shift4 Payments Inc Initiation
William Blair initiated research coverage of Shift4 Payments, Inc. (FOUR $83.10), a leading merchant acquirer or payment service provider (PSP). Shift4 operates four complementary businesses: a proprietary gateway, a leading venue payments and ticketing business, an emerging software-enabled POS, and a cross-border e-commerce acquirer.
-
Brickell Biotech Inc Initiation
William Blair initiated research coverage of Brickell Biotech, Inc. (BBI $0.21), a clinical-stage biopharmaceutical company developing therapies to treat autoimmune, inflammatory, and other debilitating diseases.
-
Fusion Pharmaceuticals and Point Biopharma Global Initiation
William Blair initiated research coverage of Fusion Pharmaceuticals Inc. (FUSN $2.53) and POINT Biopharma Global Inc. (PNT $6.81), two companies in what analyst Andy Hsieh describes as the “reignited” space of radiopharmaceuticals for the treatment of cancer.
-
MDxHealth SA Initiation
William Blair initiated research coverage of MDxHealth SA (MDXH $2.86), a commercial-stage diagnostics company providing actionable molecular diagnostic information to personalize diagnosis and treatment of prostrate cancer and other urologic diseases.
-
Owlet Inc Initiation
William Blair initiated research coverage of Owlet, Inc. (OWLT $13.66), a company offering monitoring devices and subscriptions for pediatric health, including Dream Sock, the first and only FDA-cleared pediatric health monitor on the market.
-
Social Determinants of Health
In this episode of William Blair Thinking Presents, equity research analyst Ryan Daniels dives deep into the healthcare team’s Quarterly Healthcare Mosaic report, which focuses on “food as medicine,” an emerging area in addressing social determinants of health.
-
Behavioral Healthcare Robust Demand and Ripe for Innovation
Following the COVID-19 pandemic, the behavioral healthcare industry has experienced an unprecedented surge in the need for innovation, increased access to care, and demand for services.